There are 2789 resources available
134P - Enrolment in clinical trials (CT) among patients (pts) with early breast cancer (BC)
Presenter: Daniele Presti
Session: ePoster Display
135P - Hot flashes during adjuvant hormone therapy predict treatment discontinuation and outcome among breast cancer patients
Presenter: Erwei Zeng
Session: ePoster Display
87P - Clinical development of a predictive biomarker with 58 tumor genes for dovitinib treatment of solid tumors
Presenter: Roberto Pili
Session: ePoster Display
172P - Stage-dependent prognostic value of systemic inflammatory biomarkers in early triple-negative breast cancer (TNBC)
Presenter: Guilherme Nader Marta
Session: ePoster Display
173P - What to expect from NCCN BRCA testing criteria: A retrospective cohort analysis
Presenter: Burak Aktas
Session: ePoster Display
234P - Effect of palbociclib (PAL) + endocrine therapy (ET) on time to chemotherapy (TTC) across subgroups of patients (pts) with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC): Post hoc analyses from PALOMA-2 (P2) and PALOMA-3 (P3)
Presenter: Hope Rugo
Session: ePoster Display
176P - Pathological complete response to neoadjuvant systemic therapy in 1160 initial and locally advanced breast cancer patients: Real life data on outcomes
Presenter: Monique Tavares
Session: ePoster Display
Resources:
Abstract
141P - Gene-expression pathways and dynamics during neoadjuvant chemo-free therapy predict pathologic complete response in ER+/HER2+ breast cancer (BC)
Presenter: Matteo Dugo
Session: ePoster Display
238P - BOLERO-5: A phase II study of everolimus and exemestane combination in Chinese post-menopausal women with ER+/HER2- advanced breast cancer
Presenter: Zhimin Shao
Session: ePoster Display
239P - Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients
Presenter: Marzia Del Re
Session: ePoster Display